Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma
- PMID: 17559361
- DOI: 10.1111/j.1440-1746.2007.04997.x
Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma
Abstract
Hypoxia enhances proliferation, angiogenesis, metastasis, chemoresistance, and radioresistance of hepatocellular carcinoma (HCC); suppresses differentiation and apoptosis of HCC; and consequently leads to resistance of transarterial embolization (with or without chemotherapy). Because transarterial embolization contributes to angiogenesis via inducing hypoxia, therapy combined with transarterial embolization and antiangiogenic therapy provides a new strategy for the treatment of HCC. Unfortunately, hypoxia leads to the escape of HCC cells from transarterial embolization and antiangiogenic therapy. Thus combined therapy that induces and targets hypoxia may be of benefit to HCC patients. Because angiogenesis plays an important role in recurrence of HCC after resection, antiangiogenic therapy is beneficial to HCC patients following surgical resection of the tumor.
Comment in
-
Growth factors as indicators of prognosis in liver failure.J Gastroenterol Hepatol. 2007 Aug;22(8):1171-3. doi: 10.1111/j.1440-1746.2007.05005.x. J Gastroenterol Hepatol. 2007. PMID: 17688658 No abstract available.
Similar articles
-
Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.J Hepatol. 2011 Feb;54(2):328-39. doi: 10.1016/j.jhep.2010.06.045. Epub 2010 Sep 17. J Hepatol. 2011. PMID: 21056497
-
New strategy of antiangiogenic therapy for hepatocellular carcinoma.Neoplasma. 2008;55(6):472-81. Neoplasma. 2008. PMID: 18999874 Review.
-
Vascular changes in hepatocellular carcinoma.Anat Rec (Hoboken). 2008 Jun;291(6):721-34. doi: 10.1002/ar.20668. Anat Rec (Hoboken). 2008. PMID: 18484619 Review.
-
Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice.Hepatology. 2006 May;43(5):1063-73. doi: 10.1002/hep.21149. Hepatology. 2006. PMID: 16628632
-
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.Cancer Lett. 2006 Oct 28;242(2):151-67. doi: 10.1016/j.canlet.2006.01.008. Epub 2006 Mar 27. Cancer Lett. 2006. PMID: 16564617 Review.
Cited by
-
The regulation of hypoxia-related lncRNAs in hepatocellular carcinoma.Discov Oncol. 2024 May 7;15(1):144. doi: 10.1007/s12672-024-01002-3. Discov Oncol. 2024. PMID: 38713276 Free PMC article. Review.
-
Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.Int J Biol Sci. 2024 Feb 11;20(5):1634-1651. doi: 10.7150/ijbs.92211. eCollection 2024. Int J Biol Sci. 2024. PMID: 38481819 Free PMC article.
-
Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.BMC Genomics. 2023 Dec 14;24(1):776. doi: 10.1186/s12864-023-09876-3. BMC Genomics. 2023. PMID: 38097948 Free PMC article.
-
Hypoxia induces hepatocellular carcinoma metastasis via the HIF-1α/METTL16/lnc-CSMD1-7/RBFOX2 axis.iScience. 2023 Nov 19;26(12):108495. doi: 10.1016/j.isci.2023.108495. eCollection 2023 Dec 15. iScience. 2023. PMID: 38089592 Free PMC article.
-
A novel hypoxia-associated gene signature for prognosis prediction in head and neck squamous cell carcinoma.BMC Oral Health. 2023 Nov 14;23(1):864. doi: 10.1186/s12903-023-03489-8. BMC Oral Health. 2023. PMID: 37964257 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
